Ascendis Pharma
ASND
147 hedge funds and large institutions have $5.41B invested in Ascendis Pharma in 2020 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 43 increasing their positions, 59 reducing their positions, and 21 closing their positions.
133% more call options, than puts
Call options by funds: $50.7M | Put options by funds: $21.8M
56% more capital inflows, than outflows
Capital inflows: $651M | Capital outflows: $417M
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
3.23% more ownership
Funds ownership: 81.14% → 84.37% (+3.2%)
3% more funds holding
Funds holding: 143 → 147 (+4)
27% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 59
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
+$260M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
+$94.8M |
| 3 |
Janus Henderson Group
London,
|
+$79.8M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$52.4M |
| 5 |
Putnam Investments
Boston,
Massachusetts
|
+$51.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$73.9M |
| 2 |
Marshall Wace North America
New York
|
-$37.7M |
| 3 |
Millennium Management
New York
|
-$28.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.7M |
| 5 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.5M |
ASND Hedge Fund Activity: Q1 2020 in Review
147 of the 4,550 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma (ASND) for Q1 2020, worth a combined $5.41B — down 16% from $6.42B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ASND positions and 21 closed out — a net gain of 6 holders — while 43 added to existing stakes and 59 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $260M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.9M.
- 147 institutional investors held Ascendis Pharma (ASND) as of Q1 2020, up from 143 in Q4 2019.
- Funds reported $5.41B of Ascendis Pharma stock for Q1 2020, down 16% quarter-over-quarter.
- 27 funds opened new Ascendis Pharma positions in Q1 2020 and 21 closed out, a net change of +6 holders.
- The largest Ascendis Pharma buyer in Q1 2020 was Vivo Capital, an estimated $260M added.
- The largest Ascendis Pharma seller in Q1 2020 was T. Rowe Price Associates, an estimated $73.9M sold.
Based on aggregated 13F filings for Q1 2020.